Early Identification of Potentially Cured Patients with Acute Myelogenous Leukemia — A Recent Challenge

  • Michael J. Keating
Part of the Cancer Treatment and Research book series (CTAR, volume 5)

Abstract

Historically, the treatment of adults with acute myelogenous leukemia (AML) has evolved through a number of phases. In the initial phase we saw the accumulation of information on the natural history of acute leukemia and study of the patterns of survival [1, 2]. Analysis of survival data in patients with acute leukemia who were treated with supportive care only was adequately documented and showed that half of all patients would die in less than four months and less than one patient in ten would live for one year. The early literature was concerned with documentation of spontaneous remissions, and up until 1960, there was no evidence that chemotherapy-induced remissions were of longer duration [1, 2] than those which occurred spontaneously. In addition, no accurate estimate of the response rate to chemotherapeutic agents was available, despite the fact that the ‘chemotherapy era’ in acute leukemia had been ushered in by Farber in 1949 [4].

Keywords

Hepatitis Oncol Folic Acid Cyclophosphamide Prednisone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tivey H: The natural history of untreated acute leukemia. Ann NY Acad Sci 60:322–358, 1954.PubMedCrossRefGoogle Scholar
  2. 2.
    Southam CM, Craver LF, Dargeon HW, et al.: A study of the natural history of acute leukemia with special reference to the duration of the disease and the occurrence of remissions. Cancer 4:39–59, 1951.PubMedCrossRefGoogle Scholar
  3. 3.
    Boggs DR, Wintrobe MM, Cartwright GE: To treat or not to treat acute granulocytic leukemia. II. Arch Intern Med 123:568–570, 1969.PubMedCrossRefGoogle Scholar
  4. 4.
    Farber S: Some observations on the effect of folic acid antagonists on acute leukemia and other forms of cancer. Blood 4:160, 1949.PubMedGoogle Scholar
  5. 5.
    Freireich EJ, et al.: The effect of chemotherapy on acute leukemia in the human. J Chronic Dis 14:593–607, 1961.PubMedCrossRefGoogle Scholar
  6. 6.
    Boggs DR, Wintrobe MM, Cartwright GE: The acute leukemias: an analysis of 322 cases and review of the literature. Medicine 41:163–225, 1962.PubMedCrossRefGoogle Scholar
  7. 7.
    Freireich EJ, Bodey GP, Harris JE, Hart JS: Therapy for acute granulocytic leukemia. Cancer Res 27:2573–2577, 1967.PubMedGoogle Scholar
  8. 8.
    Levin RH, Henderson E, Karon M, Freireich EJ: Treatment of acute leukemia with methyl-glyoxal-bis-guanylhydrazone (methyl GAG). Clin Pharmacol Ther 6:31–42, 1964.Google Scholar
  9. 9.
    Crosby WH: To treat or not to treat acute granulocytic leukemia. Arch Intern Med 122:79–80, 1968.PubMedCrossRefGoogle Scholar
  10. 10.
    Ellison RR, Holland JF, Weil M, Jacquillat C: Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32: 307–523, 1968.Google Scholar
  11. 11.
    Bodey GP, et al.: Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. Cancer Chemother Rep 53:59–65, 1969.PubMedGoogle Scholar
  12. 12.
    Boiron M, Jacquillat C, Weil M, Tanzier J, Levy D, Sultan C, Bernard J: Daunorubicin in the treatment of acute myelocytic leukemia. Lancet i: 330, 1969.CrossRefGoogle Scholar
  13. 13.
    Jacquillat C, Boiron M, Weil M, Tanzer J, Najean Y, Bernard J: Rubidomycin, a new agent active in the treatment of acute lymphoblastic leukaemia. Lancet ii: 27, 1966.CrossRefGoogle Scholar
  14. 14.
    Burgess MA, Garson OM, De Gruchy GC: Daunorubicin in the treatment of adult acute leukaemia. Med J Aus 1:629–635, 1970.Google Scholar
  15. 15.
    Burchenal JH: Formal discussion: Long-term survival in Burkitt’s tumor and in acute leukemia. Cancer Res 27:2616–2618, 1967.PubMedGoogle Scholar
  16. 16.
    Southwest Oncology Group: cytarabine for acute leukemia in adults: effects of schedule on therapeutic response. Arch Intern Med 133:251–259, 1974.CrossRefGoogle Scholar
  17. 17.
    Goodell B, Leventhal B, Henderson E: Cytosine arabinoside in acute granulocytic leukemia. Clin Pharmacol Ther 12:599–606, 1971.PubMedGoogle Scholar
  18. 18.
    Wiernik PH, Schimpff SC, Schiffer CA, Lichtenfeld JL, Aisner J, O’connell MJ, Fortner C: Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrime-thamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia. Cancer Treat Rep 60:41–53, 1976.PubMedGoogle Scholar
  19. 19.
    Weil M, Glidewell OJ, Jacquillat C, Levy R: Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res 33:921–928, 1973.PubMedGoogle Scholar
  20. 20.
    McCredie KB, Bodey GP, Freireich EJ, Hester JP: Chemoimmunotherapy of adult acute leukemia. Cancer (in press).Google Scholar
  21. 21.
    Jacquillat CL, Weil M, Gemon-Aucler MF, Izrael V: Clinical study of rubidazone (22 050 R.P.), a new daunorubicin-derived compound, in 170 patients with acute leukemias and other malignancies. Cancer 37:653–659, 1976.PubMedCrossRefGoogle Scholar
  22. 22.
    Gale RP, Cline MJ: High remission-induction rate in acute myeloid leukaemia. Lancet i:497–499, 1977.CrossRefGoogle Scholar
  23. 23.
    Peterson BA, Bloomfield CD, Bosl GJ, Gibbs G, Malloy M: Intensive five-drug combination chemotherapy for adult acute nonlymphocytic leukemia. Cancer 46:663–668, 1980.PubMedCrossRefGoogle Scholar
  24. 24.
    Preisler HD, Rustum Y, Henderson ES, Bjornsson S, et al.: Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood 53:455–464, 1979.PubMedGoogle Scholar
  25. 25.
    Glucksberg H, Buckner CD, Fefer A, DeMarsh Q, Coleman D, et al.: Combination chemotherapy for acute nonlymphoblastic leukemia in adults. Cancer Chemother Rep 59:1131–1137, 1975.PubMedGoogle Scholar
  26. 26.
    Keating MJ, Smith TL, McCredie KB, Bodey GP, et al.: A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer (in Press).Google Scholar
  27. 27.
    Ohno R, Hirano M, Imai K, Katsuo K, et al.: Daunorubicin, cytosine arabinoside, 6-mer-captopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myel-ogenous leukemia in adults. Cancer 36:1945–1949, 1975.PubMedCrossRefGoogle Scholar
  28. 28.
    Bernard J, Weil M, Boiron M, et al.: Acute promyelocytic leukemia. Blood 41:489–496, 1973.PubMedGoogle Scholar
  29. 29.
    Reiffers J, Raynal F, Broustet A: Acute myeloblastic leukemia in elderly patients. Treatment and prognostic factors. Cancer 45:2816–2820, 1980.PubMedCrossRefGoogle Scholar
  30. 30.
    Grann V, Erichson R, Flannery J, Finch S, Clarkson B: The therapy of acute granulocytic leukemia in patients more than 50 years old. Ann Intern Med 80:15–20, 1974.PubMedGoogle Scholar
  31. 31.
    Peterson BA, Bloomfield CD: Treatment of acute non-lymphocytic leukemia in elderly patients. A prospective study of intensive chemotherapy. Cancer 40:647–652, 1977.PubMedCrossRefGoogle Scholar
  32. 32.
    Keating MJ, Benjamin RS, McCredie KB, Bodey GP, Freireich EJ: Remission induction therapy with a rubidazone-containing combination (ROAP) in acute leukemia. Proc Am Assoc Cancer Res 18:180, 1977 (Abst. # 719).Google Scholar
  33. 33.
    Yamada K, Uetani T: Five-Year survivors with acute leukemia in Japan. Acta Haematol Jap 37:99–107, 1974.Google Scholar
  34. 34.
    Jacquillat CI, Weil M, Gemon M-F, et al.: Evaluation of 216 four-year survivors of acute leukemia. Cancer 32:286–293, 1973.PubMedCrossRefGoogle Scholar
  35. 35.
    Pavlovsky S, Muriel FS: Long-term survival in acute leukemia in Argentina. Cancer 40:1402–1409. 1977.PubMedCrossRefGoogle Scholar
  36. 36.
    Oliff A, Poplack D: Characteristics of long-term survivors in AML. Med Pediatr Oncol 5:219–223, 1973.CrossRefGoogle Scholar
  37. 37.
    Keating MJ, Bodey GP, McCredie KB, Freireich EJ: Five-year survival and remission duration in adult acute myelogenous leukemia. Proc Am Soc Clin Oncol 20:416, 1979 (Abstract).Google Scholar
  38. 38.
    Coltman CA, Jr, Freireich EJ, Savage RA, Gehan EA: Long term survival of adults with acute leukemia. Proc Am Soc Clin Oncol 20:389, 1979 (Abstract).Google Scholar
  39. 39.
    Ellison RR, Glidewell O: Improved survival in adults with acute myelocytic leukemia (AML). Proc Am Assoc Cancer Res 20:161, 1979 (Abstract).Google Scholar
  40. 40.
    Weil M, Auclerc MF, Jacquillat CL, et al.: Long term relapse free survivals (R.F.S.) in 815 patients (pts) with acute granulocytic leukemias (A.G.L.). Proc Am Soc Clin Oncol 21:444, 1980 (Abstract C-494).Google Scholar
  41. 41.
    Hewlet JS, Bodey GP, Wilson HE: Combination 6-mercaptopurine and 6-methylmercapto-purine riboside in the treatment of adult acute leukemia: a Southwest Oncology Group study. Cancer Treat Rep 63:156–158, 1979.Google Scholar
  42. 42.
    Rodriguez V, Hart JS, Freireich EJ, et al.: POMP combination chemotherapy of adult acute leukemia. Cancer 32:69–75, 1973.PubMedCrossRefGoogle Scholar
  43. 43.
    Bodey GP, Rodriguez V, Hart J, et al.: Therapy of acute leukemia with the combination of cytosine arabinoside (NSC-63878) and cyclophosphamide (NSC-26271). Cancer Chemother Rep 54:255–262, 1970.PubMedGoogle Scholar
  44. 44.
    Whitecar JP, Jr, Bodey GP, McCredie KB, et al.: Cyclophosphamide, vincristine, arabinosyl cytosine and prednisone (COAP) combination chemotherapy for adult acute leukemia. Cancer Chemother Rep 56:543–550, 1972.PubMedGoogle Scholar
  45. 45.
    Rogriguez V, Bodey GP, Gutterman JU, et al.: Combination chemotherapy of adult acute leukemia for remission induction and maintenance. In: Therapy of acute leukemias, Mandelli F, Amadori S, Mariani E (eds). Rome: Minerva Medica, 1973, pp 569–577.Google Scholar
  46. 46.
    McCredie KB, Freireich EJ, Bodey GP, Burgess MA, et al.: A study of intermittent alternating drug program reinduction therapy on the frequency and duration of response in adult acute leukemia. Med Pediatr Oncol 2:309–318, 1976.PubMedCrossRefGoogle Scholar
  47. 47.
    Bodey GP, Rodriguez V, McCredie KB, et al.: Early consolidation chemotherapy for adults with acute leukemia in remission. Med Pediatr Oncol 2:299–307, 1975.CrossRefGoogle Scholar
  48. 48.
    Bodey GP, Freireich EJ, Gehan E, et al.: Late intensification therapy for acute leukemia in remission. Chemotherapy and Immunotherapy. JAMA 235:1021–1025, 1976.PubMedCrossRefGoogle Scholar
  49. 49.
    Gutterman JU, Hersh EM, Rodriguez V, et al.: Chemoimmunotherapy of adult acute leukaemia: prolongation of remission in myeloblastic leukemia with B.C.G. Lancet ii: 1405–1409, 1974.CrossRefGoogle Scholar
  50. 50.
    Burge PS, Richards JDM, Thampson DS, et al.: Quality and quantity of survival in acute myeloid leukaemia. Lancet 621–624, 1975.Google Scholar
  51. 51.
    Armitage JO, Burns CP: Long term results of maintenance therapy in adult acute nonlym-phoblastic leukemia (ANLL) using cytosine arabinoside and thioguanine: the effect of FAB subtype on outcome. Proc Am Soc Clin Oncol 21:439, 1980 (Abstract C-477).Google Scholar
  52. 52.
    Peterson BA, Bloomfield CD: Long-term disease-free survival in acute non-lymphocytic leukemia. Blood 57:1144–1147, 1981.PubMedGoogle Scholar
  53. 53.
    Clarkson BD, Dowling MD, Gee TS, Cunningham IB, Burchenal JH: Treatment of acute leukemia in adults. Cancer 36:775–795, 1975.PubMedCrossRefGoogle Scholar
  54. 54.
    Vaughan WP, Karp JE, Burke PJ: Long chemotherapy-free remissions after single-cycle times-sequential chemotherapy for acute myelocytic leukemia. Cancer 45:859–865, 1980.PubMedCrossRefGoogle Scholar
  55. 55.
    Fiere D, Martin C, Van H-Vu, et al.: Leucémies myéloides aiguës survie supérieure à 3 ans chez 16 malades. La Nouvelle Pres Medicale 7:899–902, 1978.Google Scholar
  56. 56.
    Kawashima K, Suzuki H, Yamada K, et al.: Long-term survival in acute leukemia in Japan. A study of 304 cases. Cancer 45:2181–2187, 1980.PubMedCrossRefGoogle Scholar
  57. 57.
    Keating MJ, Smith TL, Gehan EA, et al.: Factors related to length of complete remission in adult acute leukemia. Cancer 45:2017–2029, 1980.PubMedCrossRefGoogle Scholar
  58. 58.
    Gehan EA, Smith TL, Freireich EJ, et al.: Prgnostic factors in acute leukemia. Semin Oncol 3:271–282, 1967.Google Scholar
  59. 59.
    Henderson ES, Wallace HJ, Yates J, Scharlaw C et al.: Factors influencing prognosis in adult acute myelocytic leukemia. In: Advances in the biosciences, workshop on prognostic factors in human acute leukemia, Vol. 14, Fliedner TM, Perry S (eds). New York: Pergamon Press, 1975, pp 71–82.Google Scholar
  60. 60.
    Golomb HM, Rowley JD, Vardiman JW, Testa JR, Butler A: ‘Microgranular’ acute promyelocytic leukemia: a distinct clinical, ultra-structural, and cytogenetic entity. Blood 55:253–259, 1980.PubMedGoogle Scholar
  61. 61.
    Golomb HM, Rowley JD, Vardiman JW, Baron MM, Locker G, Krasnow S: Partial delection of long arm of chromosome 17: a specific abnormality in acute promyelocytic leukemia? Arch Intern Med 136:825–828, 1976.PubMedCrossRefGoogle Scholar
  62. 62.
    Trujillo JM, Cork A, Ahearn MJ, Youness EL, McCredie KB: Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia. Blood 53:695–706, 1979.PubMedGoogle Scholar
  63. 63.
    Hoelzer D, Kurrle E, et al.: Evidence for differentiation of human leukemic blood cells in diffusion chamber culture. Blood 49:729–744, 1977.PubMedGoogle Scholar
  64. 64.
    Barton JC, Conrad ME: Beneficial effects of hepatitis in patients with acute myelogenous leukemia. Ann Intern Med 90:188–190, 1979.PubMedGoogle Scholar
  65. 65.
    Wade JC, Wiernik PH, Schimpff SC, Schiffer CA: Hepatitis prolongation of complete remission and survival in acute nonlymphocytic leukemia (ANLL) patients. Proc Am Soc Clin Oncol 21:439, 1980 (Abstract C-474).Google Scholar
  66. 66.
    Dudley FJ, Fox RA, Sherlock S: Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet i:723–726, 1972.CrossRefGoogle Scholar
  67. 67.
    Werner B, London WT: Host responses to hepatitis B infection: hepatitis B surface antigen and host proteins (editorial). Ann Intern Med 83:113–114, 1975.PubMedGoogle Scholar
  68. 68.
    Sakurai M, Sandberg AA: Chromosomes and causation of human cancer and leukemia. Correlation of karyotypes with clinical features of acute myeloblastic leukemia. Cancer 37:285–299, 1976.PubMedCrossRefGoogle Scholar
  69. 69.
    Freireich EJ, Keating MJ, Gehan EA, McCredie KB, Bodey GP, Smith T: Therapy of acute myelogenous leukemia. Cancer 42:874–882, 1978.PubMedCrossRefGoogle Scholar
  70. 70.
    Rees JKH, Sandier RM, Challener J, Hayhoe FGJ: Treatment of acute myeloid leukaemia with a triple cytotoxic regimen: DAT. Br J Cancer 36:770–776, 1977.PubMedCrossRefGoogle Scholar
  71. 71.
    Uzuka Y, Liong SK, Yamagata S: Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone DCMP two step therapy. Tohoku J Exp Med 118:217–225, 1976.PubMedCrossRefGoogle Scholar
  72. 72.
    Bodey GP, McCredie KB, Keating MJ, Freireich EJ: Treatment of acute leukemia in protected environment units. Cancer 44:431–436, 1979.PubMedCrossRefGoogle Scholar
  73. 73.
    Legha SS, Keating MJ, Zander AR, McCredie KB, Bodey GP, Freireich EJ: 4′-(9-acridinyl-amino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. Ann Intern Med 93:17–21, 1980.PubMedGoogle Scholar
  74. 74.
    Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, et al.: Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 303:473–478, 1980.PubMedCrossRefGoogle Scholar
  75. 75.
    Thomas ED, Buckner CD, Clift RA, et al.: Marrow transplantation for acute nonlympho-blastic leukemia in first remission. N Engl J Med 301:597–599, 1979.PubMedCrossRefGoogle Scholar
  76. 76.
    Blume KG, Beutler E, Bross KJ, et al.: Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 302:1041–1046, 1980.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers bv, The Hague 1982

Authors and Affiliations

  • Michael J. Keating

There are no affiliations available

Personalised recommendations